Fred Hutchinson Cancer Center

George S Laszlo

Christopher Mehlin

Colin Correnti

Roland B Walter

Anti-CD33 antibodies are described. The anti-CD33 antibodies can bind within the V-set Ig-like domain or the C2-set Ig-like domain of CD33. Epitopes FIG.A on the C2-set Ig-like domain can provide a 'pan-binding' site, to which the cognate antibody will bind regardless of whether the CD33 molecule also contains the V-set domain (as in, for example, CD33) or not (as in, for example, CD33). Alternative epitopes on the C2-set Ig-like domain are accessible for binding if the V-set domain is absent (e.g., as in CD33). Antibodies that bind an epitope on the C2-set Ig-like domain (whether they exhibit pan or V-set absent binding) are directed at novel therapeutic targets can increase therapeutic efficacy against CD-33-related disorders. Also described are molecules comprising a binding-competent domain from at least one described anti-CD33 antibody, including scFvs, bi-specific antibody molecules, chimeric antigen receptors, and immunoconjugates. Methods of use are also provided.

Growing community of inventors

Seattle, WA, United States of America

George S Laszlo